Health Care Technology
Company Overview of Molecular Health GmbH
Molecular Health GmbH develops a computational system that transforms molecular data into clinically actionable information to provide various cancer treatment options for cancer patients. The company offers TreatmentMAP, a treatment decision support solution that guides physicians and patients in the use of genetic, clinical, molecular, and efficacy data. Its solutions include TreatmentMAP-targeted panel, a test that includes various genetic variants that develop a treatment plan for newly diagnosed solid tumor cancer; and TreatmentMAP-whole exome, which analyzes various genes to identify generic variation against a patient’s normal gene set in the areas of difficult to treat cancers. The c...
Founded in 2004
Key Executives for Molecular Health GmbH
Chief Executive Officer and President
President of Molecular Health Inc - USA
Compensation as of Fiscal Year 2015.
Molecular Health GmbH Key Developments
Molecular Health Opens Berlin Office to Support Growing Demand for Digital Health Solutions
Nov 13 15
Molecular Health announced that the company has opened an office in Berlin, Germany to accelerate the growing European demand for its suite of digital health solutions. Located on Friedrichstrasse in downtown Berlin close to the government district, the new office reflects Molecular Health's continued corporate growth and will enable the company to further strengthen its relationships with policy makers and patient advocacy groups in Germany.
Molecular Health GmbH Presents at Hume Brophy 7th Annual Healthcare Conference, Oct-15-2015
Oct 12 15
Molecular Health GmbH Presents at Hume Brophy 7th Annual Healthcare Conference, Oct-15-2015 . Venue: CityPoint, 1 Ropemaker Street, London EC2Y 9SS, United Kingdom.
Molecular Health Licenses SafetyMAP(TM) to U.S. Food and Drug Administration (FDA)
Sep 9 15
Molecular Health has entered into a commercial license to provide the FDA with use of its SafetyMAPTM software - formally known as Molecular Analysis of Side Effect information (MASETM), to provide a comprehensive and dynamic analytical solution for the detection and molecular analysis of drug-induced adverse events for all marketed drugs and for predicting safety issues of new drug candidates. The license supplies the FDA with access to SafetyMAP for 10 concurrent users for a period of one year and can be extended for two additional years at the discretion of the FDA. The FDA described in its RFQ the important capability that Molecular Health's technology provides: Drug safety prediction and the evaluation of post-marketing signals depend on the ability to find scientific data that can confirm relationships among drugs, drug targets, toxicity mechanism, patient susceptibility and clinical response. This requires the ability to interrogate a wide variety of data sources, including the FAERS database, MEDLINE, gene and protein databases, FDA drug product labels, patents and other document repositories to uncover hidden relationships between scientific findings and adverse events. The creation of molecular target adverse event profiles is advancing safety science. This capability is mission critical for assessing the importance of possible safety issues pre- and post-approval and for supporting regulatory science mission at FDA.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 16, 2015
Most Searched Private Companies
Sponsored Financial Commentaries